Potentiation of the tumor-killing ability of CD8 + T cells in tumors, along with their efficient tumor infiltration, is a key element of successful immunotherapies. Several studies have indicated that tumor infiltrating myeloid cells (e.g., myeloid-derived suppressor cells (MDSCs) and tumorassociated macrophages (TAMs)) suppress cytotoxicity of CD8 + T cells in the tumor microenvironment, and that targeting these regulatory myeloid cells can improve immunotherapies. Here, we present an in vitro assay system to evaluate immune suppressive effects of monocytic-MDSCs and TAMs on the tumor-killing ability of CD8 + T cells. To this end, we first cultured naïve splenic CD8 + T cells with anti-CD3/CD28 activating antibodies in the presence or absence of suppressor cells, and then co-cultured the pre-activated T cells with target cancer cells in the presence of a fluorogenic caspase-3 substrate. Fluorescence from the substrate in cancer cells was detected by real-time fluorescence microscopy as an indicator of T-cell induced tumor cell apoptosis. In this assay, we can successfully detect the increase of tumor cell apoptosis by CD8 + T cells and its suppression by pre-culture with TAMs or MDSCs. This functional assay is useful for investigating CD8 + T cell suppression mechanisms by regulatory myeloid cells and identifying druggable targets to overcome it via high throughput screening.
Introduction
It is known that CD8 + T cells can eliminate tumor cells when they exert their full cytotoxicity. After activation of the T cell receptor (TCR), CD8 + T cells proliferate and differentiate into cytotoxic effector cells. The expanded and activated CD8 + T cells secrete cytotoxic granules, including perforin and granzymes, that are transferred into target cells and initiate various lytic pathways such as caspase-3 mediated apoptosis 1 . CD8 + T cells can also induce tumor cell apoptosis by activating receptors on target cells, such as receptors for tumor necrosis factor-α (TNFα), first apoptosis signal ligand (FasL), or TNF-related apoptosis-inducing ligand (TRAIL). Furthermore, the activated CD8 + T cells secrete interferon-γ (IFN-γ) that can suppress tumor cell proliferation and increase the sensitivity of tumor cells to CD8 + T cells via the up-regulation of FasL receptor 1 . Given the potential for CD8 + T tumor killing ability, several strategies to boost their cytotoxicity (e.g., checkpoint inhibitors, cancer vaccination, and adoptive transfer of chimeric antigen receptor (CAR) expressing T cells) have been established and shown significant therapeutic effects on certain types of cancer 2 . However, accumulating evidence suggests that tumor-infiltrating immune cells such as regulatory T cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) can suppress CD8 + T cell functions and restrict efficacy of immunotherapies 3, 4, 5 . To improve such immunotherapies, it is important to understand how immune suppressor cells limit CD8 + T cell cytotoxicity. The identification of CD8 + T cell suppression mechanisms as well as druggable targets to overcome it, will require the development and utilization of in vitro assays.
The gold standard method of measuring CD8 + T cell cytotoxicity is the chromium release assay in which the release of the radioactive probe ( 51 Cr), from target cells that are lysed by CD8 + T cells, is determined 6 . However, this assay has several drawbacks including relatively low sensitivity, high background, inability to detect early apoptotic events, hazardous disposal problems, and limited compatibility with automated liquid handling and detection to support higher throughput applications. Another common method is flow cytometric analyses in which apoptosis of target tumor cells is detected by annexin V binding + T cell function by suppressor cells. Detection of IFN-γ production from cultured T cells is another standard method to evaluate the effects of suppressor cells on T cell activation 8, 9 . However, the results from these assays do not necessarily correlate to the target cell killing ability of CD8 + T cells.
We present here an alternative functional assay to evaluate effects of suppressor cells, particularly macrophages in metastatic tumors, on the cytotoxicity of CD8 + T cells. This method determines cytotoxicity of CD8 + T cells, pre-cultured with or without the suppressor cells in the presence of anti-CD3/CD28 activating antibodies, by detecting tumor cell apoptosis, indicated by fluorescence from a fluorogenic caspase-3 substrate 6 using automated time-lapse microscopy (Figure 1) . This protocol has several advantages compared to other methods; it requires only a small number of cells, enables detection of adherent tumor cell death with high sensitivity, can image real-time effector-to-target interaction and is amenable to high throughput screening.
In this protocol, metastasis-associated macrophages (MAMs) and their progenitor monocytic-MDSCs (M-MDSCs) isolated from metastatic tumors in mice are used as suppressor cells. In mouse models of metastatic breast cancer, a distinct population of macrophages characterized as F4/80 high Ly6G -CD11b high Ly6C low accumulates in the lung containing metastatic tumors. This macrophage population is infrequently found in the normal lung and thus called metastasis-associated macrophages (MAMs) 10 . In these mouse models, another myeloid cell population, defined as F4/80 
Protocol
All procedures involving mice were conducted in accordance with licensed permission from UK Home Office (P526C60B3). Information about commercial reagents and equipment are listed in the 
Preparation of target cells that express red fluorescent protein in their nuclei
1. Obtain a target mouse cancer cell line from an appropriate source. NOTE: In this protocol, a highly metastatic derivative of E0771 mouse mammary tumor cells (E0771-LG) 13 are used. Parental E0771 cells originate from C57BL/6 mice 14 .
Thaw and maintain a vial of E0771-LG cells with Dulbecco's Modified Eagles Medium (DMEM) including 10% (v/v) fetal bovine serum (FBS)
in a cell culture incubator at 37 °C, 95% humidity, and 5% CO 2 . NOTE: It should be confirmed that cells are negative for mycoplasma. To this end, culture E0771 cells (or cells to be tested) for 2-3 days as described above (in the absence of antibiotics and antimycotics), collect 500 μL of culture medium. Centrifuge the medium at 12,419 x g for 60 s to eliminate cell debris and transfer supernatant into new tubes. Determine mycoplasma contamination using a commercially available mycoplasma test kit (refer to Table of Materials) and/or PCR 15 following the manufacturer's instructions.
3. Seed 5 x 10 3 E0771-LG cells per well into a 12-well plate, and culture the cells with 10% (v/v) FBS-DMEM overnight in an incubator at 37 °C, 95% humidity, and 5% CO 2 . NOTE: If the proliferation rate of target cells is low (population doubling time greater than 36 h), the number of cells can be increased to 1 x 10 4 . 4. Replace the medium with 1 mL of 10% (v/v) FBS-DMEM including 10 μg/mL polybrene and add 25 μL of lentiviral particles (1 x 10 6 TU/mL) encoding a nuclear restricted red fluorescent protein (mKate2, refer to Table of Materials). 5. Culture the cells for 24 h in an incubator at 37 °C, 95% humidity, and 5% CO 2 . 6. Replace the medium with 10% (v/v) FBS-DMEM and culture the cells for 24-48 h in an incubator at 37 °C, 95% humidity, and 5% CO 2 . 7. Replace the medium with 10% (v/v) FBS-DMEM including 1 μg/mL puromycin when cells start to express red fluorescent protein, and culture the cells until they are 80-90% confluent. NOTE: Concentration of puromycin will be different between target cell types and should be optimized using un-transfected cells. 8. Subculture the surviving cells for 1-3 passages with 10% (v/v) FBS-DMEM including 1 μg/mL puromycin, and cryopreserve stocks in a liquid nitrogen vapor phase storage system until use.
Isolation of suppressor cells from the tumors in mice
NOTE: In this protocol, suppressor cells (i.e., MAMs and M-MDSCs) are isolated from the lung containing metastatic tumors established by E0771-LG cells. Conditions for tissue dissociation and cell sorting should be optimized to isolate the cells from different tissues.
1. Inject 1 x 10 6 cancer cells (E0771-LG) into the tail vein of syngeneic (C57BL/6), female, 7-10 week old mice.
2. After 14 days, isolate the lung containing metastatic tumors and prepare single-cell suspensions from the perfused lungs via enzymatic digestion as previously described 11 . NOTE: In this protocol, four mice are injected with cancer cells and their metastatic lungs are combined to obtain sufficient suppressor cells. 3. Incubate the single cell suspensions with anti-mouse CD16/CD32 antibody for 30 min on ice, and stain with fluorescent antibodies to CD45, F4/80, CD11b, Ly6C, and Ly6G (refer to 
Activation and expansion of the isolated CD8 + T cells
1. Aliquot 1 x 10 5 cells per 50 μL CD8 + T cells (prepared in step 3.9) into wells of a U-bottom 96-well plate.
2. Add 1 x 10 5 cells per 50 μL suppressor cells (prepared in step 2.7) or 50 μL of E-DMEM into the wells.
3. Prepare activation medium that consists of E-DMEM, 4 x 10 4 U/mL colony-stimulating factor 1 (CSF-1), 240 U/mL interleukin-2 (IL-2), 8 μg/ mL anti-mouse CD3ε antibody, and 16 μg/mL anti-mouse CD28 antibody. NOTE: CSF-1 is not required for T cell activation, but is essential for survival of suppressor cells in this protocol (i.e., MAMs and M-MDSCs). Thus, it is retained in the co-culture of T cells with target cancer cells to maintain consistency in culture conditions. Since CSF-1 is found in nano-molar concentrations in all tissues and is required for monocyte/macrophage viability in vivo, this is a physiological context for these cells. 4. Add 50 μL of activation medium (step 4.3) and 50 μL of E-DMEM with or without reagents to be tested. 5. Place the plate into an incubator at 37 °C, 95% humidity, and 5% CO 2 and culture the cells for 4 days.
Setup of co-culture of target cells with pre-activated CD8
+ T cells 7 . Add 4 x 10 3 cells/25 μL of CD8 + T cells (step 5.3.4) into appropriate wells and mix well.
NOTE: The presence of too many cells in a well makes the analysis more difficult. In this model, a 4:1 effector: target ratio (total cell number 5 x 10 3 cells/well) was optimal, but an 8:1 ratio was suboptimal. Wells containing the following four controls are necessary to aid with data analysis: target cells at the density used for the co-culture wells (1 x 10 3 cells/well) in medium with and without caspase-3 substrate, effector cells (1 x 10 3 cells/well) in medium with and without caspase-3 substrate.
8. Add 200 μL of PBS or sterile water into all empty wells (particularly wells on the periphery of the plate) to reduce evaporation of medium from experimental wells. 9. Set the plate into a time-lapse fluorescence microscope that is maintained at 37 °C, 95% humidity, and 5% CO 2 .
NOTE: Shake the plate in a cross-pattern to distribute all cells evenly, and then allow the plate to remain at room temperature on a flat surface for 10-20 min before transferring to the incubator.
Imaging of the cells
NOTE: Detailed image acquisition settings will vary with the microscope and fluorophores used; the following general acquisition parameters should be employed for optimal results.
1. Using an appropriate autofocus routine on the microscope, acquire images covering at least 25% of the total surface area in each experimental well of the 96-well plate. 2. Set the microscope to acquire images in phase contrast as well as a fluorescent channel suitable for the nuclear-restricted red fluorescent protein (mKate2) and a fluorescent channel suitable for the green fluorogenic activated caspase-3 substrate (with excitation at 488 nm) (Figure 2) . 3. Capture images in experimental wells in phase contrast and the 2 fluorescent channels every 1 to 3 h for at least 72 h.
Image analysis using image analysis software
NOTE: Detailed image analysis settings will vary with the software used (refer to Table of Materials); the following general analysis procedures should be employed for optimal results. 1. Determine whether spectral un-mixing is required to separate the fluorescent signal emitted by target cell nuclei from that emitted by apoptotic nuclei and if required, set up an analysis protocol to accomplish this; 1. View a control well containing only target cells (mkate2-labeled) in medium without caspase-3 substrate in the green fluorescent channel. 2. Observe whether green fluorescence is being emitted by the red nuclei (nuclei appear green) 3. If green fluorescence is apparent in the nuclei, access the spectral unmixing control in the imaging software and increase the percentage of red removed from green until the green signal disappears (in our experience, this is usually 6-7% for bright mKate2 fluorescence). 4. If green fluorescence is not apparent in any nuclei, no spectral unmixing is necessary.
NOTE: This spectral unmixing correction test can also be carried out using a well of target cells in medium containing caspase-3 substrate. However, there is usually a very low level of spontaneous apoptosis in target cells (less than 10%), resulting in a few target cell nuclei emitting green fluorescence due to activation of caspase-3 rather than fluorescence bleed through. True fluorescence bleed through is evident under these conditions when green fluorescence is apparent in all nuclei. 5. View a control well containing only effector cells (nuclei unlabeled) in medium without caspase-3 substrate in the red and green channel individually. 6. Observe whether either green or red fluorescence is being emitted by the nuclei. If neither red nor green fluorescence is apparent in the individual channels no spectral unmixing is necessary. NOTE: In our experience, the mouse CD8 + T cells are not auto-fluorescent and thus no spectral unmixing is necessary for these cells.
This spectral unmixing correction test can also be carried out using a well of effector cells in medium containing caspase-3 substrate. However, there is usually some level of spontaneous apoptosis resulting in effector cell nuclei emitting green fluorescence due to activation of caspase-3. True fluorescence bleed through is evident under these conditions when green fluorescence is apparent in all nuclei.
4. Use images in the red channel from the wells containing only target cells (with caspase substrate) to determine the minimum size of target nuclei. NOTE: We used 80 µm 2 . 5. Use images in the green channel from the wells containing only effector cells (with caspase substrate) to determine the average size of apoptotic effector nuclei. NOTE: Single apoptotic effector nuclei ranged from 40 -80 µm 2 in these experiments. 6 . Set up an analysis procedure to count the number of fluorescent target cell nuclei using an appropriate minimum size restriction (e.g., minimum area, minimum diameter) (Figure 2 , target detection mask). NOTE: We used a minimum nuclei area (red fluorescence) = 80 µm 2 . 7. Set up an analysis procedure to count the number of apoptotic nuclei which are larger than the mean size of apoptotic effector nuclei (Figure  2 , size restricted apoptosis mask). NOTE: Size filter was set to 80 µm 2 (i.e., only areas of green fluorescence larger than this size were counted, thus excluding single apoptotic effector nuclei). Using these parameters increases the accuracy of the analysis in counting apoptotic target cell nuclei although some aggregates of apoptotic effector cells may be counted. 8. Set up an analysis procedure to count the number of apoptotic target cells by counting nuclei where red fluorescent signal (from step 7.6) and size-restricted green fluorescent signal (from step 7.7) significantly co-localize (Figure 2 , R/G overlap mask). NOTE: An appropriate co-localization may range from 30% to 100% of the mean size of target nuclei. Overlap size filter was set to 40 µm 2 . 9. Determine the number of apoptotic target cell nuclei as well as the number of target cell nuclei in the wells for each experimental condition over the entire time course.
Data analysis using calculation and graphing software
1. Graph the number of apoptotic target cell nuclei obtained in step 7.9 over the entire time course for the experimental wells. If multiple wells were used for each experimental condition, graphically present the results as mean ± standard deviation. 2. Calculate the apoptotic fraction of the population of target cells by dividing the number of apoptotic cells in each well by the number of target cells in each well at each time point. 3. Graph the results obtained in step 8.2. 4. Determine the area under the curve (AUC) for each curve. The peak apoptotic fraction of the population for each curve may also be determined as well as the time point at which the peak occurs, if desired. Determine whether the AUC determined for the experimental conditions are significantly different using appropriate statistical tests. NOTE: The unpaired t-test with Welch's correction was applied to the AUC results.
Representative Results
This method is based on simple co-culture of target cancer cells with effector CD8 + T cells that have been pre-cultured with or without suppressor cells in the presence of anti-CD3/CD28 activating antibodies. It detects CD8 + T cell-induced cancer cell apoptosis over time following co-culture, thus enabling evaluation of effects of suppressor cells on cytotoxicity of CD8 + T cells.
Typically, cancer cells increase green fluorescence in their nuclei following activation of a nuclear-targeting caspase biosensor when these cells make contact with CD8 + T cells that are pre-activated by antibodies in the absence of suppressor cells (Figure 3; Supplementary Movie 1) .
Green fluorescence from the caspase substrate was detectable for at least 15 h after apoptosis was initiated. Some spontaneous apoptosis of effector CD8 + T cells was also observed over time even if these cells were cultured in isolation (Figure 4; Supplementary Movie 2) . However, nuclei sizes of CD8 + T cells are smaller than those of cancer cells and thus apoptotic 'effector' cells can be excluded from apoptotic 'target' cell counts by a size restriction image analysis method (Figure 2 and Figure 4 ). Although some target cancer cells show a small rounded shape without green fluorescence, this does not affect the analysis as these cells are undergoing mitosis rather than apoptosis (Supplementary Movie  3) , and thus are excluded from apoptotic 'target' cell counts by a red/green overlap mask (Supplementary Figure 2) . Spontaneous apoptosis of target cancer cells is occasionally found even in the single culture (Supplementary Movie 3) . However, the co-culture of target cancer cells with pre-activated CD8 + T cells increased tumor cell apoptosis above the levels of spontaneous apoptosis in monoculture of cancer cells (Figure   4 ). Generally, when using an optimal ratio of target cancer cells to effector cells, a peak in the number of apoptotic target cancer cells can be observed (Figure 5A) . This peak is more distinct when the data is expressed as the apoptotic fraction of the target cell population (Figure 5B) . In this experiment the basal apoptosis of target tumor cells peaked at 24 h (with apoptotic fraction = 0.08), but CD8 + T cell-induced apoptosis reached a maximum level at 17 h (with apoptotic fraction = 0.66).
We further found that CD8 + T cells pre-incubated with MAMs or M-MDSCs could make contact with target cancer cells but this contact seemed to result in fewer instances of cancer cell apoptosis compared to CD8 + T cells pre-activated without suppressor cells (Figure 3 and Figure 4 ; Movie 5) . Although the CD8 + T cells pre-incubated with the myeloid cells occasionally induced cancer cell apoptosis, there was also some proliferation of target cancer cells that have not been stimulated to undergo apoptosis during the time course of the experiment (Supplementary Movie 6) . Consistent with these findings, the peak fraction of apoptotic cancer cells cultured with CD8 + T cells pre-incubated with myeloid cells (apoptotic fraction = 0.38 at 23 h for MDSC-E and 0.25 at 20 h for MAM-E) was significantly lower 
Supplementary Movie 4 and Supplementary

Supplementary Figure 2. Representative images of mitotic target cells. Stills from representative time-lapse movies of target E0771-
LG_NLR cell mono-culture. Top: composite images including images from phase contrast, red and green channels. Bottom: composite images (red and green channels) with red/green overlap mask. Please click here to download this file.
Supplementary Figure 3. Effects of tumor-infiltrating myeloid cells on proliferation of CD8 + T cells. (A) Representative histograms
showing dilution of fluorescent labeling with CFSE in CD8 + T cells. Naïve splenic CD8 + T cells were isolated as described in Protocol-3 and labeled with 5 µM of CFSE at 37 °C for 15 min. The labeled T cells were cultured in the presence of IL-2 and anti-CD3/CD28 activating antibodies with or without myeloid cells as described in Protocol 4. After 4 days, green fluorescence in T cells was detected by flow cytometer. (B) Division index of CD8 + T cells calculated as previously described 17 . Data are means ± SEM. *P<0.01 compared to control,
